Caligan Partners LP Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001727492

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidFocusedHealth TiltHigh Turnover how tags are computed

Q3 2026 · 25 positions · Total reported value $1.63B · Top-10 concentration 79.4% · Updated 2026-11-17

Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR

Turnover: 25.0% · 2 new · 2 cut · 3 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

In its Q3 2026 13F filing, Caligan Partners LP disclosed 25 equity positions with a combined reported value of $1.63B. The filing implies a focused portfolio: its ten largest positions account for 79.4% of reported value. HoldingsHub classifies the profile as Mid / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q3 2026 were RVMD ($402.68M), LQDA ($245.68M), ABVX ($154.27M). By sector, the heaviest allocations are Health Care 98.2%, Other 1.8%. Versus the prior quarter, allocation shifted toward Other (+0.9pp) and away from Health Care (-0.9pp).

Versus the prior quarter, Caligan Partners LP opened 2 new positions, trimmed 2 and fully exited 3, a turnover rate of 25.0% of positions. The portfolio's overlap with the prior quarter was 82% of names.

The largest new positions opened in Q3 2026 were EPRX ($10.58M), TLGYF ($2.50M).

Of the 3 positions fully exited versus the prior quarter, the largest were XENE ($53.72M), MBX ($11.04M), AGIO ($3.34M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q3 2026)

  • EPRX EUPRAXIA PHARMACEUTICALS INC · $10.58M
  • TLGYF TCGX ACQUISITION CORP · $2.50M

Fully Exited (vs previous quarter)

  • XENE XENON PHARMACEUTICALS INC · prev qtr: $53.72M
  • MBX MBX BIOSCIENCES INC · prev qtr: $11.04M
  • AGIO AGIOS PHARMACEUTICALS INC · prev qtr: $3.34M

Insider Transactions (Form 4)

Latest Caligan Partners LP buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

Transaction date Activity Security Shares Price Filing
2026-06-16 Award Liquidia Corp 5,882 — SEC filing
2026-05-19 Buy Liquidia Corp 5,300 $59.98 SEC filing
2026-05-19 Sell Liquidia Corp 5,300 $59.98 SEC filing

All insider transactions →

Fund Profile

Caligan Partners LP is an SEC-registered 13F filer based in New York, NY, United States. As of Q2 2026 it reported 26 US equity positions with a combined value of $1.71B. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).

Firm Snapshot

  • Headquarters: NEW YORK, NY, United States
  • SEC registration: 801-113810 (status: Approved), registered 2018-08-10
  • Regulatory AUM (Form ADV): $1.30B as of 2026-05-29
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 3 private funds, of which 3 hedge funds
  • Website: caliganpartners.com

Portfolio Structure

  • 26 positions · $1.71B reported value (Q2 2026)
  • Top 10 holdings = 81.5% of reported value
  • Largest position: LQDA (LIQUIDIA CORPORATION) at 37.8%
  • Average position size: $65.78M

Sector Tilt

  • Health Care 99.1%
  • (classified holdings cover 99% of value)

Quarterly Activity

  • Q2 2026: 5 new, 8 added, 3 reduced, 5 exited
  • 10 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

Sector Allocation

Health Care 98.2%
Other 1.8%
Sort by: Value · CSV
# Shares Value Weight Allocation Change
1 1.96M $402.68M 24.64%
24.64%
Add
2 8.12M $245.68M 15.04%
15.04%
Hold
3 1.56M $154.27M 9.44%
9.44%
Hold
4 2.19M $124.53M 7.62%
7.62%
Hold
5 1.55M $90.73M 5.55%
5.55%
Hold
6 2.50M $62.41M 3.82%
3.82%
Hold
7 5.88M $58.93M 3.61%
3.61%
Add
8 3.08M $57.34M 3.51%
3.51%
Add
9 1.67M $50.65M 3.10%
3.10%
Add
10 3.27M $50.10M 3.07%
3.07%
Add
11 1.51M $49.62M 3.04%
3.04%
Add
12 1.93M $36.73M 2.25%
2.25%
Hold
13 9.19M $33.90M 2.07%
2.07%
Add
14 5.96M $28.85M 1.77%
1.77%
Reduce
15 4.59M $28.83M 1.76%
1.76%
Add
16 1.44M $28.21M 1.73%
1.73%
Hold
17 8.74M $27.70M 1.70%
1.70%
Add
18 2.79M $27.61M 1.69%
1.69%
Add
19 890.21K $26.47M 1.62%
1.62%
Add
20 910.75K $19.92M 1.22%
1.22%
Add
21 1.16M $10.58M 0.65%
0.65%
New
22 1.48M $10.55M 0.65%
0.65%
Reduce
23 923.91K $4.43M 0.27%
0.27%
Hold
24 200.00K $2.50M 0.15%
0.15%
New
25 470.00K $864.80K 0.05%
0.05%
Hold

FAQ

What did Caligan Partners LP buy in 2026-Q3?

In its 2026-Q3 13F filing, Caligan Partners LP reported 25 equity positions worth $1.63B in aggregate; its largest disclosed positions were RVMD ($402.68M), LQDA ($245.68M), ABVX ($154.27M).

How large is Caligan Partners LP's portfolio?

Caligan Partners LP reported $1.63B of long equity holdings across 25 positions as of 2026-Q3. Top-10 holdings account for 79.4% of reported value.

What is Caligan Partners LP's investment style?

HoldingsHub classifies the portfolio as Mid / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/caligan-partners/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →